Ophthalmic Business News

In this episode, I discuss Samsara Vision’s SING IMT and its benefits of vision improvement for patients with AMD with Rebecca Kammer, OD, PhD.

Aviceda Therapeutics submitted an investigational new drug application to the FDA for AVD-104 for the treatment of geographic atrophy secondary to age-related macular degeneration.

Private equity has had a long involvement with and continues to stay active in the business of health care.

Lenz Therapeutics has raised $83.5 million in an oversubscribed Series B financing, according to a press release.

Photobiomodulation delivered with the Valeda light delivery system demonstrated sustained vision improvements at 24 months in patients with dry age-related macular degeneration, according to a press release from LumiThera.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the Silicon Valley Bank collapse and its impact on investing and innovation in the field of ophthalmology with Gilbert H. Kliman, MD.

A phase 3 clinical trial demonstrated positive 3-year results for bilateral intravitreal injection of Lumevoq gene therapy, with statistically significant visual acuity improvements from baseline in both treated eyes.

Let’s start by getting to the point. You should call your bank and find out what you are making on your cash.

Sight Sciences launched the Ergo-Series of its Omni surgical system for minimally invasive glaucoma surgery in the United States.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Yari L. Mitchell, of AcuFocus, reports the limited commercial release of the IC-8 Apthera IOL in the United States.